| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/08/2006 | US20060122232 4-Hydroxyfuroic acid derivatives |
| 06/08/2006 | US20060122231 Such as N-(4-tert-butylphenyl)-4-(2-pyridinyl)benzamide for treatment of urinary incontinence, pain, inflammatory thermal hyperalgesia, and/or bladder overactivity |
| 06/08/2006 | US20060122230 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators |
| 06/08/2006 | US20060122229 4,5-diarylthiazole derivatives as cb-1 ligands |
| 06/08/2006 | US20060122228 Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| 06/08/2006 | US20060122227 Process for alkylating secondary amines and the use in donepezil preparation thereof |
| 06/08/2006 | US20060122226 Crystalline forms of Donepezil base |
| 06/08/2006 | US20060122225 Asymmetric hydrogenation of enaminoesters without protecting the secondary amino group with a protective group; good asymmetric, chemical yields and workability; methyl (2R,4S)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamate |
| 06/08/2006 | US20060122224 Quinoline and quinoxaline compounds |
| 06/08/2006 | US20060122223 Substituted amino carboxylic acids |
| 06/08/2006 | US20060122222 Heterocycle substituted carboxylic acids |
| 06/08/2006 | US20060122221 N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; rheumatoid arthritis |
| 06/08/2006 | US20060122220 Method for treating HIV infection through co-administration of tipranavir and UK-427,857 |
| 06/08/2006 | US20060122219 Use of flumazenil in the production of a medicament for the treatment of cocaine dependency |
| 06/08/2006 | US20060122218 e.g. (2R,3S)-2-(2,3-Dichlorophenoxymethyl)-8-methyl-3-(2-thienyl-8-aza-bicyclo[3.2.1]octane; antidepressants; anxiolytic agents |
| 06/08/2006 | US20060122217 Combination of organic compounds |
| 06/08/2006 | US20060122216 The enantiomer of tenatoprazole and the use thereof in therapy |
| 06/08/2006 | US20060122215 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity |
| 06/08/2006 | US20060122214 Agent for prophylaxis and treatment of angiostenosis |
| 06/08/2006 | US20060122213 Azaindoles useful as inhibitors of protein kinases |
| 06/08/2006 | US20060122212 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 06/08/2006 | US20060122211 HIV integrase inhibitors, pharmaceutical compositions and methods for their use |
| 06/08/2006 | US20060122210 Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same |
| 06/08/2006 | US20060122209 Process for preparing trisubstituted pyrimidine compounds |
| 06/08/2006 | US20060122208 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| 06/08/2006 | US20060122207 Imidazol derivatives as Raf kinase inhibitors |
| 06/08/2006 | US20060122206 3-[2-[4-(5-fluoro-1H-indol-3-yl)-1,2,3,6-tetrahydro-pyridin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; antidepressant, neuroleptic, anxiolytic agent; nervous system disorders, Parkinson's disease, schizophrenia, autism, cognition activator |
| 06/08/2006 | US20060122205 Potassium salt of an HIV integrase inhibitor |
| 06/08/2006 | US20060122204 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 06/08/2006 | US20060122203 2-Hydroxymethylcyclopropylidenemethylpurines and - pyrimidines as antiviral agents |
| 06/08/2006 | US20060122202 For example, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione; use in treating prostate cancer, benign prostatic hypertrophy, breast cancer and endometriosis |
| 06/08/2006 | US20060122201 Uracil-thioether |
| 06/08/2006 | US20060122200 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
| 06/08/2006 | US20060122199 anti-invasive agent for use in the containment and/or treatment of solid tumour disease; little activity against VEGF receptor tyrosine kinase; synergistic use with other anticancer agents; 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline |
| 06/08/2006 | US20060122198 Antiepileptic agent |
| 06/08/2006 | US20060122197 Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: 1'-{[1-(4-Chlorophenyl)cyclo-pentyl]carbonyl}-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; antidiabetic agents |
| 06/08/2006 | US20060122196 Gyrase inhibitors and uses thereof |
| 06/08/2006 | US20060122195 Sulphonamide compounds that modulate chemokine receptor activity (ccr4) |
| 06/08/2006 | US20060122194 Tablet comprising efletirizine and pseudoephedrine |
| 06/08/2006 | US20060122193 E.g., Methyl 3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzyl-piperazin-1-yl)methyl]phenylcarbamate and Methyl 3-{(S)-{4-[(diethylamino)carbonyl]phenyl}[4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl]methyl}phenylcarbamate |
| 06/08/2006 | US20060122192 Chemical compounds |
| 06/08/2006 | US20060122191 N-(indolethyl-)cycloamine compounds |
| 06/08/2006 | US20060122190 Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition |
| 06/08/2006 | US20060122189 Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition |
| 06/08/2006 | US20060122188 Anticoagulants; 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methylthiazol-4-yl)methoxyquinoline; antithrombotic agents in the treatment and prevention of thrombosis |
| 06/08/2006 | US20060122187 Pyridine derivatives as H3 antagonists |
| 06/08/2006 | US20060122186 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia |
| 06/08/2006 | US20060122185 Bicyclic inhibitors of Rho kinase |
| 06/08/2006 | US20060122184 Cyanomethyl derivatives as cysteine protease inhibitors |
| 06/08/2006 | US20060122183 Synergistic; side effect reduction; melanomas; toxicity; 2,5-Dimethoxythiobenzoic Acid N-methylhydrazine; anticancer |
| 06/08/2006 | US20060122182 Bioassay of testing the compound on the biological system or sample; antihistamines; bronchodilator agents, anticholinergic agents; respiratory system disorders; 2-{(S)-1-[5-(2-methylamino)acetylamino)pentyl]pyrrolidin-3-yl}-2,2-diphenylacetamide |
| 06/08/2006 | US20060122181 Heteroaromatic pentacyclic compound and medicinal use thereof |
| 06/08/2006 | US20060122180 Therapeutic treatment |
| 06/08/2006 | US20060122179 Methods and compositions using JNK inhibitors for treatment and management of central nervous system injury |
| 06/08/2006 | US20060122178 Compounds having activity as inhibitors of apoptosis |
| 06/08/2006 | US20060122177 Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites |
| 06/08/2006 | US20060122176 such as 5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione, used for the treatment and/or prophylaxis of autoimmune, cardiovascular or neurodegenerative disorders, inflammatory or kidney diseases, bacterial or viral infections, platelet aggregation, cancer, transplant rejection or lung injuries |
| 06/08/2006 | US20060122175 Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites |
| 06/08/2006 | US20060122174 Antiviral treatment |
| 06/08/2006 | US20060122173 Il-8 receptor antagonists |
| 06/08/2006 | US20060122172 Novel 1,4-diazabicycloalkane derivatives, their preparation and use |
| 06/08/2006 | US20060122171 5-[(1-Ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; antiproliferative agents; modulating cell differentiation,migration, and chemoinvasion; endothelial growth factor-modulated diseases; antiarthritic agents; graft versus host diseases |
| 06/08/2006 | US20060122170 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof |
| 06/08/2006 | US20060122169 Succinoylamino benzodiazepines as inhibitors of Abeta protein production |
| 06/08/2006 | US20060122168 Malonamide derivatives |
| 06/08/2006 | US20060122167 C6-and c9-substituted isoxazoline derivatives and their use as anti-depressants |
| 06/08/2006 | US20060122166 Chemokine receptors; inhibition of HIV replication; acquired immune deficiency syndrome (AIDS); cis N-(4-{2-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]ethyl}-4-phenylcyclohexyl)-1H-pyrazole-4-carboxamide |
| 06/08/2006 | US20060122165 Crystalline cefdinir |
| 06/08/2006 | US20060122164 Carboxylic acid esters of pharmaceutical compounds |
| 06/08/2006 | US20060122163 adding temozolomide with dissolution enhancing agent is selected from L-histidine, L-threonine, L-asparagine, L-serine, and L-glutamine; freeze drying |
| 06/08/2006 | US20060122162 Methods of using temozolomide formulation intrathecally in the treatment of cancers |
| 06/08/2006 | US20060122161 Methods for treating or preventing cancer by preventing, inhibiting, or arresting cell cycling |
| 06/08/2006 | US20060122160 Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation |
| 06/08/2006 | US20060122159 Pharmaceutical formulation |
| 06/08/2006 | US20060122158 Pharmaceutical application of 15- or 16-substituted testosterone analogues |
| 06/08/2006 | US20060122157 2-Methylene-18,19-dinor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 06/08/2006 | US20060122156 Heteroaryl compounds |
| 06/08/2006 | US20060122155 Carbacyclic phosphatidic acid derivative |
| 06/08/2006 | US20060122154 1-(2-(Hydroxymethyl)-5-thiolanyl)pyrrolo[2.3d]pyrimidine derivatives or their phosphates: 4-amino-7-(2-C-methyl-4-thio- beta -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; hepatitis C virus |
| 06/08/2006 | US20060122153 Antineoplastic ether lipid compounds with modifications at the sn-2 carbon |
| 06/08/2006 | US20060122152 Heparin for the treatment of ocular pathologies |
| 06/08/2006 | US20060122151 Composition containing an association of aspirin and an anti-Xa oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin |
| 06/08/2006 | US20060122150 Pharmaceutical composition and method for treating a joint-capsule arthropathy |
| 06/08/2006 | US20060122149 Extraction and purification method for cereal beta-glucan |
| 06/08/2006 | US20060122148 High affinity receptors for helicobacter pylori and use thereof |
| 06/08/2006 | US20060122147 Combination preparation of hyaluronic acid and at least oe local anesthetic and the use thereof |
| 06/08/2006 | US20060122146 Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| 06/08/2006 | US20060122145 2-Aminocarbonyl-9H-purine derivatives |
| 06/08/2006 | US20060122144 Treats neoplastic disorders, infections from fungal or fungal-like organisms and other parasites |
| 06/08/2006 | US20060122143 Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| 06/08/2006 | US20060122142 DNA vaccines for farm animals, in particular bovines and porcines |
| 06/08/2006 | US20060122141 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers |
| 06/08/2006 | US20060122129 from Xanthoceras sorbifolia; 3-O-[ beta -D-galactopyranosyl(1 --> 2)]- alpha -L-arabinofuranosyl(1 --> 3)- beta -D-glucuronopyranosyl-21,22-O-diangeloyl-3 beta ,15 alpha ,16 alpha ,21 beta ,22 alpha ,28-hexahydroxyolean-12-ene; ovarian, skin, prostate, leukocytes, and bone cancer cell growth inhiitor |
| 06/08/2006 | US20060122128 3,6-Bicyclolides |
| 06/08/2006 | US20060122127 Methods for reducing the side effects associated with mirtzapine treatment |
| 06/08/2006 | US20060122126 (1S)-1,5-anhydro-1-[3-(1-benzothiene-2-ylmethyl)phenyl-D-glucitol and derivatives are Na+-glucose cotransporter inhibitors and are used to treat diabetes and related diseases such as insulin-resistance and obesity |
| 06/08/2006 | US20060122125 Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
| 06/08/2006 | US20060122124 Therapeutic agent |
| 06/08/2006 | US20060122123 Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester |
| 06/08/2006 | US20060122115 Use of SERP-1 as an antiplatelet agent |